Bavarian Nordic has two projects in infectious diseases, both at an early development stage: HIV and RSV. The company is seeking to establish partnerships in the early development stage once proof of concept is obtained.
MVA-BN® HIV multiantigen Therapeutic and prophylactic HIV vaccine, Phase I/II
MVA-BN® RSV Prophylactic vaccine, Preclinical
